◼ Archived
Business
Stroke survivors get FDA-approved daily pill shown to cut repeat risk by 26%
FDA approves first daily pill proven to cut recurrent stroke risk by 26%, reshaping secondary prevention for millions of survivors.
2 trends tracked about this subject — the full history, oldest to newest below.
FDA approves first daily pill proven to cut recurrent stroke risk by 26%, reshaping secondary prevention for millions of survivors.
New research indicates GLP-1 weight-loss medications like Mounjaro and Zepbound may offer therapeutic benefits for the one billion people with sleep apnea.